Helping people with alcohol-related liver disease take up alcohol treatment
Tests tailored alcohol treatment options for people with alcohol-related liver disease.
Key facts
- Who runs it
- Henry Ford Health System
- Where
- Detroit, United StatesSee the site
- Trial code
- Registry title
- Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
- Status
- Recruiting
- People taking part
- 268 people, planned
- Started
- 28 Jan 2026
- Expected to end
- Feb 2030
- Type of study
- Interventional, 6 groups
- Treatments tested
- ENGAGE-ALD Application (APP)
- Treatment Facilitation bundle
- Enhanced Usual Care
- Record updated
- 3 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with alcohol-related liver disease who drank alcohol in the past 6 months. They must not have had alcohol use treatment in the past 1 month. Participants are seen at University of Michigan hepatology clinics or are patients in UM Hospitals.
- Age
- 18 Years and older
- Sex
- All
- Disease stage
- A documented diagnosis of alcohol-related liver disease (ALD). Any amount of alcohol use within the past 6 months.
- Earlier treatment
- No alcohol use treatment in the past 1 month. This includes counseling, recovery groups such as Alcoholics Anonymous, church support groups, inpatient or intensive outpatient programs, and telehealth versions of these.
- Biomarker or test result
- Recent alcohol use can be shown by a positive alcohol test in the medical record, such as blood alcohol level, urinary ethyl glucuronide, urinary ethyl sulfate, or phosphatidylethanol. Interview or chart review also counts.
Main reasons for not taking part
- Serious thinking problems, such as Westhaven grade 2 or higher hepatic encephalopathy (brain changes from liver disease) or a Short Blessed Test score >=10
- Being evaluated for, listed for, or already having had a liver transplant
- Unable to read, speak or understand English
- Already enrolled in the multidisciplinary ALD clinic at Michigan Medicine
- Past history of not following the rules of earlier clinical or research studies
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Willingness to comply with all study procedures and availability for the duration of the study
- Willing and able to provide informed consent
- Enrolled at University of Michigan (UM) hepatology clinics or inpatients at UM Hospitals
- Documented diagnosis of alcohol-related liver disease (ALD) (per protocol)
- Recent alcohol use of any amount within the past 6 months as assessed by either patient interview, medical chart review, or positive alcohol biomarker (e.g. blood alcohol level, urinary ethyl glucuronide, urinary ethyl sulfate, or phosphatidylethanol) in the medical record
- No alcohol use treatment within the past 1 month including, but not limited to:; Any professionally lead therapy with a mental health counselor (such as, one-on-one therapy, group therapy, couples or family therapy) with a primary aim of alcohol abstinence or reduction in alcohol use; Community-based alcohol recovery groups (such as, Alcoholics Anonymous, SMART Recovery, Celebrate Recovery, Refuge Recovery); Community-based church support groups primarily focused on alcohol abstinence or reduction in use; Residential (inpatient) alcohol treatment; Intensive outpatient programs; Any telehealth version of the above options
- Access to a Smartphone or computer for purposes of follow-up. Those who do not have a Smartphone will be provided one along with a calling/data plan at no cost to subject by the study team for the duration of the research stud
- Ability to speak and comprehend English
Who cannot take part
- Undergoing active evaluation for liver transplantation, is listed for liver transplant, or is post-transplantation
- History of nonadherence to previous clinical or research studies
- Substantially cognitively impaired as evidenced by Westhaven grade 2 or higher hepatic encephalopathy or a score >=10 on the Short Blessed Test for cognitive impairment
- Any other medical condition or circumstance that precludes safe and meaningful participation in the study
- Unable to provide voluntary informed consent for any reason
- Unable to read or understand English
- Is enrolled in the multidisciplinary ALD clinic at Michigan Medicine
Where in United States
- Henry Ford HealthDetroit, United StatesContact: Matthew MelicanTaking people
About the trial
What the trial wants to find out
The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.
The 6 groups in the trial
- Enhanced usual care (EUC)Treatment being tested
Eligible participants randomized will be given this for stage 1 of treatment (three months) and stage 2 (three months) if participants engaged in alcohol treatment during the first stage of treatment.
Treatment: Enhanced Usual Care
- ENGAGE-ALD application (app)Treatment being tested
Eligible participants randomized to this arm will be given this for stage 1 (three months) of treatment and stage 2 (three months) if participants engaged in alcohol treatment during the first stage of treatment.
- ENGAGE-ALD app then Treatment Facilitation BundleTreatment being tested
Eligible participants randomized to this arm will be given this for stage 1 of treatment (three months). Participants that are non-responders (did not engage in alcohol treatment) will be re-randomized and assigned to the Treatment Facilitation bundle for stage 2 (three months).
Treatment: ENGAGE-ALD Application (APP) and Treatment Facilitation bundle
- Enhanced usual care then Treatment Facilitation BundleTreatment being tested
Eligible participants randomized to this arm will be given this for stage 1 of treatment (three months). Participants that are non-responders (did not engage in alcohol treatment) will be re-randomized and assigned to the Treatment Facilitation bundle for stage 2 (three months).
Treatment: Treatment Facilitation bundle and Enhanced Usual Care
- ENGAGE-ALD app then Enhanced usual careTreatment being tested
Eligible participants randomized to this arm will be given this for stage 1 (three months) of treatment. Participants that are non-responders (did not engage in alcohol treatment) will be re-randomized to the EUC arm stage 2 (three months).
Treatment: ENGAGE-ALD Application (APP)
- Enhanced usual care then Enhanced usual careTreatment being tested
Eligible participants randomized to this arm will be given this for stage 1 of treatment (three months). Participants that are non-responders (did not engage in alcohol treatment) will be rerandomized to the Enhanced usual care arm stage 2 (three months).
Treatment: Enhanced Usual Care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Enhancing Alcohol Treatment Engagement in ALD Patients
- Plain-language title
- Helping people with alcohol-related liver disease take up alcohol treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 3 February 2026